Related topics: protein · drug · molecules · compounds · new drugs

Hunting for TB's most vulnerable genes

Developing drugs to combat tuberculosis, or TB, can be frustrating business. A gene essential to the bacteria's lifecycle is discovered, scientists rush to develop drugs that inhibit the target, and then—disappointment. ...

Harnessing AI to discover new drugs inspired by nature

Artificial intelligence (AI) is able to recognize the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated. Moreover, AI helps to find molecules that have the same effect ...

COVID gets quantum treatment for drug discovery

Since the first known case of COVID-19 in December 2019, the disease has infected over 180 million people and killed nearly four million. A successful group of vaccines that target the coronavirus's spike protein has started ...

Breakthrough for tracking RNA with fluorescence

Researchers at Chalmers University of Technology, Sweden, have succeeded in developing a method to label mRNA molecules, and thereby follow, in real time, their path through cells, using a microscope—without affecting their ...

page 1 from 22

Drug discovery

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and/or designed.

In the past most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new approach has been to understand how disease and infection are controlled at the molecular and physiological level and to target specific entities based on this knowledge.

The process of drug discovery involves the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy. Once a compound has shown its value in these tests, it will begin the process of drug development prior to clinical trials.

Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. Information on the human genome, its sequence and what it encodes has been hailed as a potential windfall for drug discovery, promising to virtually eliminate the bottleneck in therapeutic targets that has been one limiting factor on the rate of therapeutic discovery.[citation needed] However, data indicates that "new targets" as opposed to "established targets" are more prone to drug discovery project failure in general[citation needed] This data corroborates some thinking underlying a pharmaceutical industry trend beginning at the turn of the twenty-first century and continuing today which finds more risk aversion in target selection among multi-national pharmaceutical companies.[citation needed]

This text uses material from Wikipedia, licensed under CC BY-SA